Focused ultrasound enhances central nervous system delivery of Bevacizumab for malignant glioma treatment

Radiology

Volumn 281, Issue 1, 2016, Pages 99-108

  Liu, Hao Li ^a   Hsu, Po Hung ^a,b   Lin, Chung Yin ^a   Huang, Chiun Wei ^b   Chai, Wen Yen ^a,b   Chu, Po Chun ^a   Huang, Chiung Yin ^b   Chen, Pin Yuan ^b   Yang, Liang Yo ^c   Kuo, John S ^d   Wei, Kuo Chen ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c CHINA MEDICAL UNIVERSITY   (Taiwan)

^d UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; EOSIN; GADOLINIUM PENTETATE MEGLUMINE; GALLIUM 68; HEMATOXYLIN; ANGIOGENESIS INHIBITOR; CONTRAST MEDIUM; GADOLINIUM PENTETATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG PENETRATION; GLIOBLASTOMA; HIGH INTENSITY FOCUSED ULTRASOUND; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIMIT OF QUANTITATION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; BRAIN NEOPLASMS; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE MODEL; GLIOMA; LONGITUDINAL STUDY; MICROBUBBLE; PROCEDURES; TREATMENT OUTCOME; ULTRASOUND THERAPY;

ANGIOGENESIS INHIBITORS; ANIMALS; BEVACIZUMAB; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; BRAIN NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GADOLINIUM DTPA; GLIOMA; LONGITUDINAL STUDIES; MAGNETIC RESONANCE IMAGING; MICE; MICROBUBBLES; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME; ULTRASONIC THERAPY;

EID: 84989237497     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2016152444     Document Type: Article

References (28)

1. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet 2012;379(9830): 1984-1996.
2. Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3(1):24-40.
3. Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009;5(11):610-620.
4. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359(6398):843-845.
5. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 2009;27(28):4733-4740.
6. Taylor J, Gerstner ER. Anti-angiogenic therapy in high-grade glioma (treatment and toxicity). Curr Treat Options Neurol 2013;15 (3):328-337.
7. Hynynen K, McDannold N, Sheikov NA, Jolesz FA, Vykhodtseva N. Local and reversible blood-brain barrier disruption by noninvasive focused ultrasound at frequencies suitable for trans-skull sonications. Neuroimage 2005;24(1):12-20.
8. Hynynen K, McDannold N, Vykhodtseva N, Jolesz FA. Noninvasive MR imaging-guided focal opening of the blood-brain barrier in rabbits. Radiology 2001;220(3):640-646.
9. White PJ, Clement GT, Hynynen K. Longitudinal and shear mode ultrasound propagation in human skull bone. Ultrasound Med Biol 2006;32(7):1085-1096.
10. Liu HL, Hua MY, Chen PY, et al. Blood-brain barrier disruption with focused ultrasound enhances delivery of chemotherapeutic drugs for glioblastoma treatment. Radiology 2010; 255(2):415-425.
11. Liu HL, Huang CY, Chen JY, Wang HY, Chen PY, Wei KC. Pharmacodynamic and therapeutic investigation of focused ultrasoundinduced blood-brain barrier opening for enhanced temozolomide delivery in glioma treatment. PLoS One 2014;9(12):e114311.
12. Wei KC, Chu PC, Wang HY, et al. Focused ultrasound-induced blood-brain barrier opening to enhance temozolomide delivery for glioblastoma treatment: a preclinical study. PLoS One 2013;8(3):e58995.
13. Aryal M, Vykhodtseva N, Zhang YZ, McDannold N. Multiple sessions of liposomal doxorubicin delivery via focused ultrasound mediated blood-brain barrier disruption: a safety study. J Control Release 2015;204:60-69.
14. Treat LH, McDannold N, Zhang Y, Vykhodtseva N, Hynynen K. Improved anti-tumor effect of liposomal doxorubicin after targeted blood-brain barrier disruption by MRI-guided focused ultrasound in rat glioma. Ultrasound Med Biol 2012;38(10):1716-1725.
15. Kinoshita M, McDannold N, Jolesz FA, Hynynen K. Noninvasive localized delivery of Herceptin to the mouse brain by MRIguided focused ultrasound-induced bloodbrain barrier disruption. Proc Natl Acad Sci U S A 2006;103(31):11719-11723.
16. Chu PC, Chai WY, Hsieh HY, et al. Pharmacodynamic analysis of magnetic resonance imaging-monitored focused ultrasound-induced blood-brain barrier opening for drug delivery to brain tumors. BioMed Res Int 2013;2013:627496.
17. Chai WY, Chu PC, Tsai MY, et al. Magneticresonance imaging for kinetic analysis of permeability changes during focused ultrasound-induced blood-brain barrier opening and brain drug delivery. J Control Release 2014;192:1-9.
18. Pardridge WM. Drug and gene delivery to the brain: the vascular route. Neuron 2002; 36(4):555-558.
19. Rapoport SI. Blood-brain barrier in physiology and medicine. New York, NY: Raven, 1976.
20. Ewing JR, Brown SL, Lu M, et al. Model selection in magnetic resonance imaging measurements of vascular permeability: Gadomer in a 9L model of rat cerebral tumor. J Cereb Blood Flow Metab 2006;26(3): 310-320.
21. Rubenstein JL, Kim J, Ozawa T, et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000;2(4):306-314.
22. Kunkel P, Ulbricht U, Bohlen P, et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001; 61(18):6624-6628.
23. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 2007;13(4):1253-1259.
24. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009;27(5):740-745.
25. Chinot OL, de La Motte Rouge T, Moore N, et al. AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Adv Ther 2011;28(4):334-340.
26. Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014;370(8):709-722.
27. O'Reilly MA, Hynynen K. Blood-brain barrier: real-time feedback-controlled focused ultrasound disruption by using an acoustic emissions-based controller. Radiology 2012; 263(1):96-106.
28. Arvanitis CD, Livingstone MS, Vykhodtseva N, McDannold N. Controlled ultrasoundinduced blood-brain barrier disruption using passive acoustic emissions monitoring. PLoS One 2012;7(9):e45783.